Doxepin — $0 on Listed Strengths
Doxepin is $0 on listed strengths only. Other strengths are not a blanket $0.
Doxepin Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $89.99 |
$0 on listed strengths: 100mg Capsules (max 90); 10mg Capsules (max 90); 150mg Capsules (max 90); 25mg Capsules (max 90); 50mg Capsules (max 90); 75mg Capsules (max 90)
About Doxepin
Doxepin is a prescription medication. Ask your doctor if Doxepin is right for you.
Other strengths and forms of Doxepin
Conditions Treated with Doxepin
How to Check Doxepin Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Doxepin at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Insomnia
Also listed for Insomnia (Short-term)
Other medications in Sleep Disorders
What Doxepin is approved for (FDA label)
Doxepin tablets are indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration. Doxepin tablets are indicated for the treatment of insomnia characterized by difficulties with sleep maintenance. ( 1 , 14 )
Source: Read the full FDA label on DailyMed. Label effective date: June 18, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Doxepin (FDA label)
Doxepin tablets are an immediate-release, round, biconvex, beveled edged tablets for oral administration available in strengths of 3 mg and 6 mg. The tablets are white (3 mg) or blue with mottled appearance (6 mg) and are debossed with D7 or DX1, respectively, on one side and are plain on the other side. Doxepin tablets are not scored. 3 mg and 6 mg tablets. Tablets not scored. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: b198ade7-fe78-437e-82b4-693dfe45ab51. SPL document ID: bfe69bed-a77f-4fa8-adef-a300fb87b7f9. Label effective date: June 18, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Doxepin (FDA label)
The following serious adverse reactions are discussed in greater detail in other sections of labeling: Abnormal thinking and behavioral changes [see Warnings and Precautions ( 5.2 )]. Suicide risk and worsening of depression [see Warnings and Precautions ( 5.3 )]. CNS Depressant effects [see Warnings and Precautions ( 5.4 )]. The most common treatment-emergent adverse reactions, reported in greater than or equal to 2% of patients treated with doxepin tablets, and more commonly than in patients treated with placebo, were somnolence/sedation, nausea, and upper respiratory tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ajanta Pharma USA Inc. at 1-855-664-7744 and or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The pre-marketing development program for doxepin tablets included doxepin HCl exposures in 1017 subjects (580 insomnia patients and 437 healthy subjects) from 12 studies conducted in the United States. 863 of these subjects (580 insomnia patients and 283 healthy subjects) participated in six randomized, placebo-controlled efficacy studies with doxepin tablets doses of 1 mg, 3 mg, and 6 mg for up to 3-months in duration.
Source: FDA prescribing information (DailyMed). Set ID: b198ade7-fe78-437e-82b4-693dfe45ab51. SPL document ID: bfe69bed-a77f-4fa8-adef-a300fb87b7f9. Label effective date: June 18, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Doxepin (FDA label)
Hypersensitivity to doxepin hydrochloride, inactive ingredients, or other dibenzoxepines. ( 4.1 ) Co-administration with Monoamine Oxidase Inhibitors (MAOIs): Do not administer if patient is taking MAOIs or has used MAOIs within the past two weeks. ( 4.2 ) Untreated narrow angle glaucoma or severe urinary retention. ( 4.3 ) 4.1. Hypersensitivity Doxepin tablets are contraindicated in individuals who have shown hypersensitivity to doxepin HCl, any of its inactive ingredients, or other dibenzoxepines. 4.2. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Do not administer doxepin tablets if patient is currently on MAOIs or has used MAOIs within the past two weeks.
Source: FDA prescribing information (DailyMed). Set ID: b198ade7-fe78-437e-82b4-693dfe45ab51. SPL document ID: bfe69bed-a77f-4fa8-adef-a300fb87b7f9. Label effective date: June 18, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Doxepin (FDA label)
Need to Evaluate for Co-morbid Diagnoses: Reevaluate if insomnia persists after 7 to 10 days of use. ( 5.1 ) Abnormal thinking, behavioral changes, complex behaviors: May include “Sleep-driving” and hallucinations. Immediately evaluate any new onset behavioral changes. ( 5.2 ) Depression: Worsening of depression or suicidal thinking may occur. Prescribe the least amount feasible to avoid intentional overdose. ( 5.3 ) CNS-depressant effects: Use can impair alertness and motor coordination. Avoid engaging in hazardous activities such as operating a motor vehicle or heavy machinery after taking drug. ( 5.4 ) Do not use with alcohol. ( 5.4 , 7.3 ) Potential additive effects when used in combination with CNS depressants or sedating antihistamines.
Source: FDA prescribing information (DailyMed). Set ID: b198ade7-fe78-437e-82b4-693dfe45ab51. SPL document ID: bfe69bed-a77f-4fa8-adef-a300fb87b7f9. Label effective date: June 18, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Doxepin (FDA label)
MAO inhibitors: Doxepin tablets should not be administered in patients on MAOIs within the past two weeks. ( 4.2 ) Cimetidine: Increases exposure to doxepin. ( 7.2 ) Alcohol: Sedative effects may be increased with doxepin. ( 7.3 , 5.4 ) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin. ( 7.4 , 5.4 ) Tolazamide: A case of severe hypoglycemia has been reported. ( 7.5 ) 7.1. Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7.2. Cimetidine Doxepin tablets exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes.
Source: FDA prescribing information (DailyMed). Set ID: b198ade7-fe78-437e-82b4-693dfe45ab51. SPL document ID: bfe69bed-a77f-4fa8-adef-a300fb87b7f9. Label effective date: June 18, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.